Drugs for Portal Vein Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 91)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Heparin, bovine |
Approved, Investigational, Withdrawn |
Phase 4 |
|
9005-49-6 |
22833565 9812414 772 |
Synonyms:
Adomiparin
alpha-Heparin
Ariven
Arteven
Bemiparin
BOVINE HEPARIN
Calcilean
CALCIPARINE
Certoparin
CLEXANE
Clexane®|enoxaparin sodium|Lovenox®|PK-10169|RP-54563
Clivarin
Clivarine
DALTEPARIININATRIUM
Dalteparin
DALTEPARIN SODIUM
dalteparin sodium|Fragmin®
DALTEPARIN SODNÁ SÅ®L
DALTEPARIN SODYUM
DALTEPARINA SODICA
DALTEPARINA SÓDICA
DALTEPARINE SODIQUE
DALTÉPARINE SODIQUE
DALTEPARINNATRIUM
DALTEPARIN-NATRIUM
DALTEPARIN-NÁTRIUM
DALTEPARINO NATRIO DRUSKA
DALTEPARINUM NATRICUM
DALTEPARYNA SODOWA
Depo-Heparin
ENOXAPARIN
ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE)
ENOXAPARIN SODIUM SALT
Eparina
Eparina [DCIT]
Fluxum
FR-860
FRAGMIN
Fragmin A
Fragmin B
Fraxiparin
Hed-Heparin
Hepalean
HEPARIN
Heparin Cy 216
|
HEPARIN FRAGMENT KABI 2165
Heparin Leo
Heparin Lock Flush
HEPARIN SODIUM
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparina
HEPARINATE
Heparine
HEPARINIC ACID
Heparinsodiumsalt
Heparinum
Hepathrom
HepFlush®
HEP-LOCK
KABI-2165
Leparan
Lipo-Hepin
LIQUAEMIN
Liquaemin Sodium
Liquemin
LOVENOX
LOVENOX (PRESERVATIVE FREE)
LOW LIQUEMINE
Low molecular weight heparin sodium
Multiparin
Novoheparin
Pabyrin
PANHEPRIN
Parnaparin
Parnaparin sodium
Parvoparin
PK-10169
Pularin
Reviparin
RP-54563
Sandoparin
SODIUM HEPARIN
Sublingula
TEDELPARIN
Thromboliquine
Unfractionated heparin
Vetren
Vitrum AB
|
|
2 |
|
Ethiodized oil |
Approved, Investigational |
Phase 4 |
|
8008-53-5 |
|
Synonyms:
|
3 |
|
Cisplatin |
Approved |
Phase 4 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
4 |
|
Warfarin |
Approved |
Phase 4 |
|
81-81-2, 129-06-6 |
54678486 |
Synonyms:
(Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin
(Phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine
(S)-4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone
1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone
200 Coumarin
3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin
3-(Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin
3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin
4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin
4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin
4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin
4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine
4oh-Coumarin deriv.
aldo Brand OF warfarin sodium
Aldocumar
Antigen brand OF warfarin sodium
Apotex brand OF warfarin sodium
apo-Warfarin
Arab rat death
Arab rat deth
Athrombin
Athrombine-K
Athrombin-K
Bailly brand OF warfarin sodium
Boots brand OF warfarin sodium
Bristol-myers squibb brand OF warfarin sodium
Brumolin
Choice
Compound 42
CO-Rax
Coumadin
Coumadin Tabs
Coumadin®|Marevan®|panwarfin
Coumadine
Coumafen
Coumafene
Coumaphen
Coumaphene
Coumarins
Coumefene
Cov-R-tox
D-CON
delta-CON
Dethmor
Dethnel
Dicusat e
DL-3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
Eastern states duocide
Estedi brand OF warfarin sodium
fasco Fascrat powder
Frass-ratron
Genpharm brand OF warfarin sodium
Gen-warfarin
Goldshield brand OF warfarin sodium
Jantoven
Killgerm sewarin P
Kumader
Kumadu
Kumatox
Kypfarin
Latka 42
Liqua-tox
Maag rattentod cum
Marevan
|
Mar-frin
Martin'S mar-frin
Maveran
Mouse pak
NSC-59813
PANWARFIN
Place-pax
Potassium, warfarin
Prothromadin
Rat & mice bait
Rat and mice bait
Rat-alpha-way
Rat-a-way
Rat-beta-gon
Rat-b-gon
Rat-gard
Rat-kill
Rat-mix
Rat-O-cide #2
Rat-O-cide no. 2
Rat-ola
Ratorex
Ratox
Ratoxin
Ratron
Ratron g
Rats-NO-more
Ratten-koederrohr
Rattenstreupulver neu schacht
Rattenstreupulver new schacht
Rattentraenke
Rat-trol
Rattunal
RAX
RCR Grey squirrel killer concentrate
Rodafarin
Rodafarin c
ro-Deth
Rodex
Rodex blox
Rosex
Rough & ready mouse mix
Rough and ready mouse mix
Sakarat
Sewarin
Sodium, warfarin
Sofarin
Solfarin
Sorexa plus
Spray-trol brand roden-trol
Tedicumar
Temus W
Tintorane
Tox-hid
Twin light rat away
Vampirinip II
Vampirinip III
Waran
Warf 42
Warfant
Warfarat
WARFARIN
Warfarin Plus
Warfarin potassium
Warfarin Q
Warfarin sodium
Warfarina
Warfarine
Warficide
Warfilone
Zoocoumarin
|
|
5 |
|
Benzocaine |
Approved, Investigational |
Phase 4 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
6 |
|
Tannic acid |
Approved |
Phase 4 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
7 |
|
Nadroparin |
Approved, Investigational |
Phase 4 |
|
|
|
Synonyms:
|
8 |
|
Apixaban |
Approved |
Phase 4 |
|
503612-47-3 |
10182969 |
Synonyms:
APIXABAN
APIXABÁN
Apixabanum
BMS 562247-01
|
BMS-562247
BMS-562247|Eliquis®
BMS-562247-01
Eliquis
|
|
9 |
|
Reviparin |
Approved, Investigational |
Phase 4 |
|
9041-08-1 |
|
Synonyms:
INNOHEP
Innohep®|tinzaparin sodium
LNH1
LNH-1
LOGIPARIN
|
Reviparin sodium
TINZAPARIN
Tinzaparin sodium
Tinzaparina
|
|
10 |
|
Acetylsalicylic acid |
Approved, Vet_approved |
Phase 4 |
|
50-78-2 |
2244 |
Synonyms:
2-(ACETYLOXY)BENZOATE
2-(ACETYLOXY)benzoIC ACID
2-Acetoxybenzenecarboxylate
2-ACETOXYBENZENECARBOXYLIC ACID
2-ACETOXYBENZOATE
2-ACETOXYBENZOIC ACID
2-CARBOXYPHENYL ACETATE
8-HOUR BAYER
A.S.A.
A.S.A. Empirin
ACARD
ACENTERINE
Acesal
Acetal
ACETARD
ACETICYL
Acetilsalicilico
Acetilum acidulatum
Acetisal
ACETOL
ACETONYL
ACETOPHEN
Acetophen®|acetylsalicylic acid|Aspirin®
ACETOSAL
ACETOSALIC ACID
ACETOSALIN
Acetoxybenzoic acid
ACETYLIN
Acetylsal
ACETYLSALIC ACID
ACETYLSALICYLATE
ACETYLSALICYLIC ACID
Acetylsalicylsaeure
Acetylsalicylsaure
ACETYLSALICYLSÄURE
ACETYONYL
ACETYSAL
ACETYSALICYLIC ACID
Acid, acetylsalicylic
Acide 2-(acetyloxy)benzoique
ACIDE 2-(ACÉTYLOXY)BENZOÏQUE
Acide acetylsalicylique
ACIDE ACÉTYLSALICYLIQUE
Acido acetilsalicilico
ÁCIDO ACETILSALICÍLICO
Acido O-acetil-benzoico
ACIDUM ACETYLSALICYLICUM
Acimetten
Acisal
ACYLPYRIN
Adiro
ALKA RAPID
Aloxiprimum
ANADIN ALL NIGHT
ANGETTES 75
ASA
Asagran
ASATARD
Ascoden-30
Aspalon
Aspec
ASPERGUM
ASPIRDROPS
ASPIRIN
Aspirina
Aspirine
Aspro
ASPRO CLR
Asteric
Azetylsalizylsaeure
AZETYLSALIZYLSÄURE
BAY1019036
BAYER EXTRA STRENGTH
Bayer Extra Strength Aspirin For Migraine Pain
BENASPIR
Bialpirina
BIALPIRINIA
Bi-prin
BUFFERIN
CAPRIN
CARDIOASPIRINA
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
DANAMEP
Decaten
Delgesic
Dispril
DISPRIN CV
|
DISPRIN DIRECT
Dolean pH 8
Duramax
DURLAZA
EASPRIN
ECM
ECOLEN
ECOTRIN
EMPIRIN
ENDOSPRIN
ENDYDOL
ENPRIN
Entericin
Enterophen
Enterosarein
Enterosarine
Entrophen
EQUI-PRIN
Extren
GENCARDIA
Globentyl
Globoid
Helicon
Idragin
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LEVIUS
Magnecyl
MAX STRGH ASPRO CLR
MEASURIN
Micristin
MICROPIRIN EC
Neuronika
Novid
NSC-27223
NSC-406186
Nu-seals
NU-SEALS 300
NU-SEALS 600
NU-SEALS 75
Nu-seals aspirin
NU-SEALS CARDIO 75
O-(ACETYLOXY)BENZOATE
O-(ACETYLOXY)BENZOIC ACID
O-accetylsalicylic acid
O-ACETOXYBENZOATE
O-ACETOXYBENZOIC ACID
O-Acetylsalicylate
O-ACETYLSALICYLIC ACID
O-CARBOXYPHENYL ACETATE
O-Carboxyphenyl acetic acid
PAYNOCIL
PERSISTIN
PHARMACIN
Pirseal
PLATET
PLATET 300
Polopirin
POLOPIRYNA
POSTMI 300
POSTMI 75
PREMASPIN
RHEUMINTABLETTEN
RHODINE
Rhonal
Salacetin
SALCETOGEN
SALETIN
Salicylate acetate
SALICYLIC ACID ACETATE
Salicylic acid acetic acid
Salicylic acid, acetate
SALOSPIR
Solfrin
SOLPRIN
SOLPRIN ACID
SOLPYRON
Solupsan
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
TASPRIN
TEMPERAL
TOLDEX
TRIAMINICIN
Triple-sal
Vanquish
VAZALORE
Xaxa
Yasta
Zorprin
|
|
11 |
|
Dipyridamole |
Approved |
Phase 4 |
|
58-32-2 |
3108 |
Synonyms:
Antistenocardin
Apo dipyridamole
Apo-dipyridamole
Apotex brand OF dipyridamole
Ashbourne brand OF dipyridamole
ATTIA
B01AC07
Belmac brand OF dipyridamole
Berlin chemie brand OF dipyridamole
Berlin-chemie brand OF dipyridamole
Boehringer ingelheim brand OF dipyridamole
Cardoxin
Cerebrovase
CEREBROVASE 100
CEREBROVASE 25
Cléridium
Cleridium 150
Curantil
Curantyl
Dipiridamol
Dipyramidole
Dipyridamine
Dipyridamol
|
DIPYRIDAMOLE
Dipyridamolum
Dipyudamine
Dypyridamol
IPRAD brand OF dipyridamole
IV PERSANTINE
Kurantil
Miosen
MODAPLATE
Novo dipiradol
Novo-dipiradol
Novopharm brand OF dipyridamole
NSC-515776
OFCRAM PR
Persantin
PERSANTIN RET
Persantine
Persantine®
PYRIDANTIN
RA-8
Usaf ge-12
VASYROL
|
|
12 |
|
Fibrinolytic Agents |
|
Phase 4 |
|
|
|
13 |
|
Anticoagulants |
|
Phase 4 |
|
|
|
14 |
|
Calcium heparin |
|
Phase 4 |
|
|
|
15 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
16 |
|
Gelatin Sponge, Absorbable |
|
Phase 4 |
|
|
|
17 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
18 |
|
Factor Xa Inhibitors |
|
Phase 4 |
|
|
|
19 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Serine Proteinase Inhibitors |
|
Phase 4 |
|
|
|
21 |
|
Antithrombins |
|
Phase 4 |
|
|
|
22 |
|
Antithrombin III |
|
Phase 4 |
|
|
|
23 |
|
Heparin, Low-Molecular-Weight |
|
Phase 4 |
|
|
|
24 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
25 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
26 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
27 |
|
Analgesics |
|
Phase 4 |
|
|
|
28 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
29 |
|
Antipyretics |
|
Phase 4 |
|
|
|
30 |
|
Phosphodiesterase Inhibitors |
|
Phase 4 |
|
|
|
31 |
|
Cyclooxygenase Inhibitors |
|
Phase 4 |
|
|
|
32 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
33 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
34 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
35 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
36 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
37 |
|
Serine |
Investigational, Nutraceutical |
Phase 4 |
|
56-45-1 |
5951 |
Synonyms:
(-)-Serine
(2S)-2-Amino-3-hydroxypropanoate
(2S)-2-Amino-3-hydroxypropanoic acid
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-b,b-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-BETA,BETA-carotene-3,3'-diol
(3R,3'r,6S)-4,5-DIDEHYDRO-5,6-dihydro-β,β-carotene-3,3'-diol
(S)-(-)-Serine
(S)-2-Amino-3-hydroxypropanoate
(S)-2-Amino-3-hydroxy-propanoate
(S)-2-Amino-3-hydroxypropanoic acid
(S)-2-Amino-3-hydroxy-propanoic acid
(S)-a-Amino-b-hydroxypropionate
(S)-a-Amino-b-hydroxypropionic acid
(S)-alpha-Amino-beta-hydroxypropionate
(S)-alpha-Amino-beta-hydroxypropionic acid
(S)-b-Amino-3-hydroxypropionate
(S)-b-Amino-3-hydroxypropionic acid
(S)-beta-Amino-3-hydroxypropionate
(S)-beta-Amino-3-hydroxypropionic acid
(S)-Serine
(S)-Α-amino-β-hydroxypropionate
(S)-Α-amino-β-hydroxypropionic acid
2-Amino-3-hydroxypropanoate
2-Amino-3-hydroxypropanoic acid
3-Hydroxy-L-alanine
|
alpha-Amino-beta-hydroxypropionic acid
beta-Hydroxyalanine
beta-Hydroxy-L-alanine
b-Hydroxyalanine
b-Hydroxy-L-alanine
Bo-xan
e 161b
L Serine
L-(-)-Serine
L-2-Amino-3-hydroxypropionate
L-2-Amino-3-hydroxypropionic acid
L-3-Hydroxy-2-aminopropionate
L-3-Hydroxy-2-aminopropionic acid
L-3-Hydroxy-alanine
L-Ser
L-Serin
L-Serine
S
Ser
Serina
SERINE
Serinum
Xanthophyll
Î’-hydroxyalanine
Î’-hydroxy-L-alanine
|
|
38 |
|
Rivaroxaban |
Approved |
Phase 3 |
|
366789-02-8 |
9875401 |
Synonyms:
BAY 59-7939
BAY 59-7939|Xarelto®
BAY59-7939
BAY-59-7939
|
JNJ39039039
JNJ-39039039
RIVAROXABAN
XARELTO
|
|
39 |
|
Propranolol |
Approved, Investigational |
Phase 3 |
|
318-98-9, 525-66-6 |
62882 4946 |
Synonyms:
(+-)-1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-NAPHTHYLOXY)-2-HYDROXY-3-ISOPROPYLAMINOPROPANE HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHOXY)-PROPAN-2-OL HYDROCHLORIDE
1-(ISOPROPYLAMINO)-3-(1-NAPHTHYLOXY)-2-PROPANOL HYDROCHLORIDE
1-(Isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-ISOPROPYLAMINO-3-(1-NAPHTHOXY)-PROPAN-2-OL-HYDROCHLORIDE
Anaprilin
Anapriline
ANGILOL
APSOLOL
Avlocardyl
AY-64043
AY-64043-
BEDRANOL
BEDRANOL S.R.
Bedranol®|Hemangiol®|Inderal®|propranolol hydrochloride
Beprane
BERKOLOL
Betachron
Betadren
BETADUR CR
Betalong
Beta-Neg
BETA-PROGRANE MR
beta-Propranolol
Beta-Tablinen
Beta-Timelets
b-Propranolol
CARDINOL
Caridolol
Corpendol
Deralin
Dexpropranolol
Dl-Propranolol Hydrochloride
Dociton
DUPROMEX
Duranol
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HALF BETA-PROGRANE MR
HALF PROPANIX LA
HALF PROPATARD LA
HALF-BEPRANE CR
HALF-BETADUR CR
HALF-INDERAL LA
HEMANGEOL
Hydrochloride, propranolol
ICI-45520
Inderal
INDERAL LA
|
Inderide
INDERIDE-40/25
INDERIDE-80/25
Indobloc
INNOPRAN
INNOPRAN XL
Intermigran
Kemi S
LEDERPRONOL
LOPRANOL LA
Migrastat
NSC-91523
Obsidan
Obzidan
Oposim
Prano-Puren
PROBETA LA
Propanalol
Propanix
PROPANIX LA
PROPANIX-10
PROPANIX-160
PROPANIX-160 SR
PROPANIX-40
PROPANIX-80
Propanolol
PROPATARD LA
Prophylux
Propranalol
PROPRANOLOL
PROPRANOLOL HCL
Propranolol Hcl Intensol
Propranolol hydrochloride
PROPRANOLOL HYDROCHLORIDE INTENSOL
Propranololo
Propranololum
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
RAPRANOL SR
Rapynogen
Reducor
Reducor Line
Rexigen
SAGITTOL
Servanolol
SLO-BLOK
SLO-PRO
SLOPROLOL
Sumial
SYPROL
TESNOL
Î’-propranolol
|
|
40 |
|
Simvastatin |
Approved |
Phase 3 |
|
79902-63-9 |
54454 |
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8AR)-8-{2-[(2R,4R)-4-HYDROXY-6-OXOOXAN-2-YL]ETHYL}-3,7-DIMETHYL-1,2,3,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL 2,2-DIMETHYLBUTANOATE
2,2-Dimethylbutyrate, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
C10AA01
Cholestat
Coledis
Colemin
Corolin
Denan
Eucor
FLOLIPID
Kolestevan
Labistatin
LACERSA
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
Medipo
MK-0733
MK-733
MK-733|Zocor®
Modutrol
Nivelipol
Nor-vastina
Pantok
Pepstatin
RANZOLONT
|
Rechol
Rendapid
Simcor
Simovil
SIMVADOR
SIMVASTATIN
Simvastatin [Usan:Ban:Inn]
SIMVASTATIN HYDROXY ACID
Simvastatin lactone
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
SIV691
Sivastin
Statin
Synvinolin
Valemia
Vasotenal
Velostatin
Vytorin
Zocor
ZOCOR HEART-PRO
Zocord
|
|
41 |
|
Sorafenib |
Approved, Investigational |
Phase 3 |
|
284461-73-0 |
216239 |
Synonyms:
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
BAY 43-9006
BAY 43-9006|BAY-439006|Nexavar®
BAY-43-9006
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
|
Nexavar
SORAFENIB
Sorafénib
Sorafenib N oxide
Sorafenib N-oxide
Sorafenib tosylate
Sorafenibum
|
|
42 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
43 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
44 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
45 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
46 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
47 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
48 |
|
Hypolipidemic Agents |
|
Phase 3 |
|
|
|
49 |
|
Anticholesteremic Agents |
|
Phase 3 |
|
|
|
50 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 61)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial |
Unknown status |
NCT02630095 |
Phase 4 |
Nadroparin Calcium and Warfarin |
2 |
A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis |
Unknown status |
NCT02398357 |
Phase 4 |
Nadroparin Calcium and Warfarin |
3 |
Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy |
Unknown status |
NCT02238444 |
Phase 4 |
Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin |
4 |
Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients:A Randomized Controlled Trial |
Completed |
NCT04173429 |
Phase 4 |
Nadroparin calcium, warfarin |
5 |
Initiation of NWS Anticoagulation Therapy After Oesophageal Variceal Band Ligation Was Safe in Portal Vein Thrombosis Patients With Cirrhosis and Acute Variceal Bleeding: A Multi-central Randomized Controlled Trial |
Completed |
NCT04976543 |
Phase 4 |
nadroparin calcium-warfarin sequential anticoagulation |
6 |
Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension |
Completed |
NCT02247414 |
Phase 4 |
Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin |
7 |
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis |
Completed |
NCT03007212 |
Phase 4 |
|
8 |
Efficacy and Safety of Apixaban, Warfarin and Aspirin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy |
Recruiting |
NCT04645550 |
Phase 4 |
Apixaban;Warfarin;Aspirin;Dipyridamole;Low molecular weight heparin |
9 |
Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study |
Unknown status |
NCT02627053 |
Phase 3 |
rivaroxaban |
10 |
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis |
Unknown status |
NCT03193502 |
Phase 3 |
rivaroxaban |
11 |
Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV) |
Unknown status |
NCT02853526 |
Phase 3 |
Propranolol;Warfarin |
12 |
Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study. |
Unknown status |
NCT01798329 |
Phase 3 |
|
13 |
A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism |
Completed |
NCT02585713 |
Phase 3 |
Apixaban;Dalteparin |
14 |
Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis |
Completed |
NCT02250391 |
Phase 3 |
NPB-06;Placebo |
15 |
Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. |
Completed |
NCT02555111 |
Phase 3 |
Xarelto |
16 |
A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding |
Completed |
NCT01095185 |
Phase 3 |
Simvastatin;Placebo |
17 |
SBRT Sequential TACE Combined With Sorafenib Versus Sorafenib Alone in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus:A Single-center Randomized Controlled Study |
Recruiting |
NCT04387695 |
Phase 3 |
Sorafenib |
18 |
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT) |
Terminated |
NCT01887717 |
Phase 3 |
Sorafenib |
19 |
An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis |
Withdrawn |
NCT03422419 |
Phase 3 |
Heparin |
20 |
Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis |
Completed |
NCT03009461 |
Phase 2 |
Sorafenib |
21 |
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion: PORTAL Study |
Recruiting |
NCT05625893 |
Phase 2 |
|
22 |
Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and Camrelizumab for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. |
Recruiting |
NCT05166239 |
Phase 2 |
Lenvatinib 1;Camrelizumab 1;Lenvatinib 2;Camrelizumab 2 |
23 |
A Randomized, Double-blinded, Controlled Phase II Study of Combination Therapy of HAIC (Hepatic Arterial Infusion Chemotherapy), HLX10 (PD-1 Antibody) and HLX04 (VEGF Antibody) Compared With HAIC and Placebo in Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis |
Not yet recruiting |
NCT04947826 |
Phase 2 |
HLX10 (PD-1 antibody);HLX04 (VEGF antibody);Placebo |
24 |
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With Stereotactic Body Radiotherapy for Hepatocellular Carcinoma Patients With Portal Vein Thrombosis. |
Not yet recruiting |
NCT05286320 |
Phase 1, Phase 2 |
Lenvatinib/Pembrolizumab plus SBRT combinations |
25 |
Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698 |
Terminated |
NCT00769873 |
Phase 2 |
Enoxaparin |
26 |
Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis: A Randomized, Double-blinded, Placebo - Controlled Trial (PiVoT-AC Trial) |
Withdrawn |
NCT04055389 |
Phase 1 |
Antithrombin III |
27 |
Role of Endoscopic Ultrasound Guided Fine Needle Aspiration of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma |
Unknown status |
NCT03902678 |
|
|
28 |
Comparison in Portal Flow After Sleeve Gastrectomy and Mini Gastric Bypass |
Unknown status |
NCT02733770 |
|
|
29 |
The Effect of Rifaximin on Portal Vein Thrombosis in Cirrhotic Patients |
Unknown status |
NCT03631147 |
|
Rifaximin |
30 |
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis |
Unknown status |
NCT02309788 |
|
|
31 |
STUDY OF THE ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS |
Unknown status |
NCT03322696 |
|
|
32 |
Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study. |
Unknown status |
NCT02597218 |
|
|
33 |
A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis |
Completed |
NCT05541562 |
|
|
34 |
Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis |
Completed |
NCT02069457 |
|
|
35 |
Outcomes of Surgical Strategies for Living Donor Liver Transplantation to Patients With Portal Vein Thrombosis |
Completed |
NCT05132192 |
|
|
36 |
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis |
Completed |
NCT03201367 |
|
Rivaroxaban |
37 |
EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications |
Completed |
NCT03477149 |
|
|
38 |
Analysis of Neutrophil Extracellular Traps in Hypercoagulability and Portal Vein Thrombosis in Liver Cirrhosis Patients |
Completed |
NCT05012501 |
|
|
39 |
Risk Factors for Recurrence of Thrombosis or Thrombotic Extension, in the Event of Acute Non-cirrhotic Portal Vein Thrombosis Secondary to a Local Cause. |
Completed |
NCT05360641 |
|
|
40 |
A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma in Patients With Portal Vein Thrombosis |
Completed |
NCT01556282 |
|
|
41 |
Portal Vein Thrombosis Relevance On Liver Cirrhosis: Italian Venous Thrombotic Events Registry |
Completed |
NCT01470547 |
|
|
42 |
Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Treatment Combined With Propranolol for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial |
Completed |
NCT01326949 |
|
|
43 |
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms |
Completed |
NCT01816256 |
|
|
44 |
Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis |
Completed |
NCT01177631 |
|
|
45 |
Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization With Large Hepatocellular Carcinomas or Associated Portal Vein Thrombosis |
Completed |
NCT02848638 |
|
|
46 |
Neoadjuvant Transartery Chemoembolization Plus Artery Infusion Chemotherapy With Surgery Versus Surgery Alone for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: a Randomized Clinical Trial |
Recruiting |
NCT04181931 |
|
|
47 |
Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt |
Recruiting |
NCT03031717 |
|
|
48 |
Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank |
Recruiting |
NCT03541057 |
|
|
49 |
Prospective Evaluation of Coagulation Status and Thromboelastometry Guided Management of Genetic and Acquired Thrombophilia in Patients With Portal Vein Thrombosis and Budd-Chiari Syndrome |
Recruiting |
NCT05123326 |
|
|
50 |
Efficacy and Safety of Dabigatran in Patients With Cirrhosis and Portal Vein Thrombosis-A Randomized Placebo Controlled Trial |
Recruiting |
NCT04433481 |
|
Dabigatran |
|